Buffalo, N.Y.-based Roswell Park Comprehensive Cancer Center achieved an overall one-year survival rate of 92.6% after standardizing allogeneic hematopoietic cell transplant processes and workflows, according to a study published July 5 in Transplantation and Cellular Therapy.
The most recent data from the Center for International Blood and Marrow Transplant Research shows that the national one-year overall survival rate was 80% between 2017 and 2022.
The higher survival rate achieved by Roswell Park followed a 2024 systemwide redesign of cell transplant procedures. Changes included in the redesign were: a “shortened menu” of less toxic treatment regimens; standardized and prioritized patient-donor matching; post-transplant cyclophosphamide to reduce the incidence of graft-versus-host disease; expanded transplant access to patient populations not typically considered “good candidates”; and implementation of an early-discharge outpatient care model.
“Allogeneic transplant is one of the most complex medical procedures done today. However, despite that complexity, less — done well — beats more,” Shernan Holtan, MD, chief of blood and marrow transplant and co-first author of the study, said in a July 6 news release from Roswell Park. “Less toxic regimens, modern donor selection and the right use of cyclophosphamide gave our patients something extraordinary — a 90%-plus chance of being alive and well a year out.”
Read the full study here.
